References
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR (Text Revision). Washington: American Psychiatric Association, 1994
- Kessler R, Brandenburg N, Lane M, et al. Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication. Psychol Med 2005;35:1073–82
- Wittchen H-U. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 2002;16: 162–71
- Greenburg P, Sisitky T, Kessler R, et al. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 1999;60:427–35
- Canadian Clinical Practice Guidelines. Management of anxiety disorders: generalized anxiety disorder. Can J Psychiatry 2006;51:51–5S
- Compendium of Pharmaceuticals and Specialties. Ottawa: Canadian Pharmacists Association, 2005:1923
- Goodman W, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from doubleblind, placebo-controlled trials. J Affect Disord 2005;87:161–7
- Baldwin D, Reines E, Guiton C, et al. Escitalopram therapy for major depression and anxiety disorders. Ann Pharmacother 2007;41:1583–92
- Bielski R, Bose A, Chang C-C. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005;17:65–9
- CADTH. Guidelines for Economic Evaluationof Pharmaceuticals: Canada. Ottawa: Canadian Agency for Drug and Technologies in Health, 2006
- Maier W, Buller R, Philipp M, et al. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord 1988;14:61–8
- Wan G, Zhang H, Tedeschi M, et al. Estimation of symptomfree days in generalized anxiety disorder. Curr Med Res Opin 2006;22:587–91
- Ministry of Health and Long-Term Care. Schedule of Benefits for Physician Services under the Health Insurance Act. Toronto: Ontario Ministry of Health and Long-Term Care, 2007
- StatCan. Average hourly wages of employees by selected characteristics and profession, unadjusted data, by province (monthly). Available at: http://www.statcan.ca/ [Accessed: 2007 Dec 20]
- Stinnett A, Paltiel D. Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means. Med Decis Making 1997;17:483–9
- Guest J, Russ J, Lenox-Smith A. Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom. Eur J Health Econ 2005;6:136–45
- Issakidis C, Sanderson K, Corry J, et al. Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders. Psychol Med 2004;34:19–35
- Heuzenroeder L, Donnelly M, Haby M, et al. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Aust N Z J Psychiatry 2004;38:602–12
- Koerner N, Dugas M, Savard P, et al. The economic burden of anxiety disorders in Canada. Can Psychol 2004;45:191–201
- Stein M, Roy-Byrne P, Craske M, et al. Functional impact and health utility of anxiety disorders in primary care outpatients. Med Care 2005;43:1164–70
- Wetherell J, Thorp S, Patterson T, et al. Quality of life in geriatric generalized anxiety disorder: a preliminary investigation. J Psychiatr Res 2004;38:305–12
- Piccinelli M. Comorbidity of depression and generalized anxiety: is there any distinct boundary? Curr Opin Psychiatry 1998;11:57–60
- Jacobi F, Wittchen H, Holting C, et al. Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS). Psychol Med 2004;34:597–611
- Dubovsky S. Generalized anxiety disorder: new concepts and psychopharmacologic therapies. J Clin Psychiatry 1990;51:3–10